1113 ECP Inipharm
BioCentury & Getty Images

Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I

Inipharm, led by former Mavupharma executives, will use its $35 million series A round

Read the full 499 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE